Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma
収録刊行物
-
- Clinical Lymphoma Myeloma and Leukemia
-
Clinical Lymphoma Myeloma and Leukemia 19 (6), 356-364.e3, 2019-06
Elsevier BV